Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

DIGITAL CONTENT

8 NEWS #PharmaBuzz

media
8 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

8DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 308362-25-6, Ridinilazole [inn], Smt19969, Smt-19969, Ridinilazole [usan], Chembl3753858

Molecular Formula

C₂₄H₁₆N₆

Molecular Weight

388.4 g/mol

InChI Key

UHQFBTAJFNVZIV-UHFFFAOYSA-N

FDA UNII

06DX01190R

Ridinilazole is a narrow-spectrum antibiotic with potential activity against Clostridioides difficile infection (CDI). Upon oral administration, ridinilazole exerts its bactericidal activity against C. difficile through inhibition of cell division. This suppresses bacterial toxin production and inhibits the associated inflammatory response. Compared to other antibiotics that treat C. difficile, ridinilazole does not deplete intestinal bacteria and preserves the intestinal bacterial activity and the associated bile acid metabolome.

1 2D Structure

Ridinilazole

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-pyridin-4-yl-6-(2-pyridin-4-yl-3H-benzimidazol-5-yl)-1H-benzimidazole

2.1.2 InChI

InChI=1S/C24H16N6/c1-3-19-21(29-23(27-19)15-5-9-25-10-6-15)13-17(1)18-2-4-20-22(14-18)30-24(28-20)16-7-11-26-12-8-16/h1-14H,(H,27,29)(H,28,30)

2.1.3 InChI Key

UHQFBTAJFNVZIV-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1=CC2=C(C=C1C3=CC4=C(C=C3)N=C(N4)C5=CC=NC=C5)NC(=N2)C6=CC=NC=C6

2.2 Other Identifiers

2.2.1 UNII

06DX01190R

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (2,2' Bis(4-pyridyl) 3h,3'h 5,5' Bibenzimidazole

2. 2,2'-dipyridin-4-yl-1h,1'h-5,5'-bibenzimidazole

3. Smt19969

2.3.2 Depositor-Supplied Synonyms

1. 308362-25-6

2. Ridinilazole [inn]

3. Smt19969

4. Smt-19969

5. Ridinilazole [usan]

6. Chembl3753858

7. 5,5'-bi-1h-benzimidazole, 2,2'-di-4-pyridinyl-

8. 06dx01190r

9. 2,2'-di(pyridin-4-yl)-1h,1'h-5,5'-bibenzo[d]imidazole

10. 2-pyridin-4-yl-6-(2-pyridin-4-yl-3h-benzimidazol-5-yl)-1h-benzimidazole

11. 2,2'-di(pyridin-4-yl)-1h,1'h-5,5'-bi(benzimidazole)

12. P-pyben

13. Unii-06dx01190r

14. Ridinilazole [who-dd]

15. Schembl413723

16. Schembl17867397

17. Schembl19235713

18. Gtpl10853

19. Dtxsid101028337

20. Smt19969smt19969

21. Bdbm50134759

22. Mfcd28963972

23. Who 10075

24. Zinc113778168

25. Cs-6591

26. Db15308

27. Lx-0216

28. Hy-16753

29. D80826

30. Q25102246

31. 2,2'-dipyridin-4-yl-1h,1'h-5,5'-bibenzimidazole

32. 2,2'-bis(4-pyridyl)-3h,3'h-5,5'-bibenzimidazole

33. 2-(pyridin-4-yl)-6-[2-(pyridin-4-yl)-1h-1,3-benzodiazol-5-yl]-1h-1,3-benzodiazole

2.4 Create Date

2007-08-09

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₁₆N₆
Molecular Weight	388.4 g/mol
XLogP3	3.9
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	3
Exact Mass	388.14364454 g/mol
Monoisotopic Mass	388.14364454 g/mol
Topological Polar Surface Area	83.1 Å²
Heavy Atom Count	30
Formal Charge	0
Complexity	524
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of Clostridium difficile infection

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Ridinilazole manufacturers, exporters & distributors on PharmaCompass

Ridinilazole

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

8 Drugs in Development

DIGITAL CONTENT

8 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

8DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?